A distinguished panel of analysts, including voices from Cantor Fitzgerald, WBB Securities, and B. Riley FBR,
In case you missed it, here is this week’s big news roundup in the Life Science sector.
INN brings the latest from the last day of the Biotech Showcase conference in San Francisco.
Miss the Biotech Showcase Conference in San Fransisco? Don’t worry, the Investing News Network was there on the floor of the show taking in all the action. Here’s a look at day two of the conference.
A new user fee and the lack of resolution on a returning tax has manufacturers worried about rising costs in a medical device industry that’s already facing increasing expenses.
At day one of the Biotech Showcase Conference in San Fransisco, the Investing News Network attended a panel discussion on the outlook for biotech–which shows promise in 2018.
At the first day of the Biotech Showcase Conference in San Fransisco, a panel discussion on the FDA discusses the new leadership and initiatives from the agency.
Miss the Biotech Showcase conference in San Fransisco? Don’t worry, the Investing News Network was there on the floor of the show. Here’s a look at day one of the conference.
On the first day of the Biotech Showcase conference INN attended a panel of gene therapy experts in the public sector, to evaluate the near future of the industry and the challenges it still faces today.
Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce that Mr. Douglas Mason has accepted the position of Interim CEO.
By Pia Rivera
Beleave Inc. (“Beleave” or the “Company”) (CSE:BE,OTCQX:BLEVF) is pleased to announce that it has signed a letter of intent with Seven Oaks Cannabis Inc. (“Seven Oaks”) for Seven Oaks to carry Beleave products if awarded a cannabis retail license by the Government of Manitoba (the “Manitoba Government”). Seven Oaks is
The Investing News Network takes a look at the major developments from the world of biotech in 2017.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it will present at the Digital Medicine & Medtech Showcase at Biotech Showcase(TM).
Mergers and acquisitions across the board, alongside a new tax plan, could spark new highs for the biotech industry in 2018.
The Investing News Network takes a look at what could be the landscape for the pharma industry and its investors moving forward into 2018.